OTTAWA, November 16, 2005 -- Validian Corporation (OTC BB: VLDI)

Validian Corporation Announces Suite of Groundbreaking Secure Data-Exchange Solutions For Market Verticals

First Solution Meets Crucial Needs in Healthcare Industry

OTTAWA, November 16th, 2005—Validian Corporation (OTC BB: VLDI), a leader in the research and development of innovative application-level security software and solutions for public and private enterprises, today announced that it is introducing a suite of secure data-exchange solutions. Validian’s first solution, tailored for medical devices, pharmaceutical and bio-technology companies, enhances medical research by securing the exchange of sensitive research and trial data.

"The ability to capture and collect clinical research and product-performance data rapidly and efficiently is crucial for any organization engaged in research and development tests and trials," said Mike Demster, Vice President of Biomedical Business Development for the Memphis Regional Chamber. "Sending data electronically saves time and money, but the risks of theft, disclosure and subsequent prosecution or loss of critical trade secrets, accumulated investment in intellectual property and competitive advantage are huge. Validian’s cost-effective software product secures the electronic exchange of research and test data, and provides significant advantage for any medical devices, pharmaceutical or bio-technology company."

By securing the electronic exchange of sensitive patient and product-performance data between physicians participating in research and trials and the research databases, Validian eliminates the risk of theft, compromise or accidental loss of patient health information (PHI), expedites the capture and collection of research and test data, and minimizes the risk of errors and information leaks.

"Validian has delivered a software product that provides complete security for sensitive PHI in transit, demonstrating once again that it’s the technology leader when it comes to HIPAA compliance," said Bruce Benn, President and CEO of Validian Corporation. "Theft or premature disclosure of test and research data can result in prosecution under HIPAA. Industrial espionage, when valuable proprietary information is stolen and sold or given to competitors, can be equally as devastating with loss of competitive advantage, market share and stock price."

About Validian
Validian Corporation provides software products that help public and private enterprises address the increasingly complex issues surrounding application security. Validian ASIT is an application-security software framework that protects the exchange of information among applications. Validian ASI operates at the application layer, where the majority of attacks now occur, and protects mission-critical applications against unauthorized access, malicious code and other forms of attack. Validian Flash Communicator uses the inherent security of Validian ASI to deliver secure, authenticated file- and message-exchange capabilities from virtually any Internet-connected computer in the world. Cost-effective, simple to deploy and easy to manage, Validian ASI and Validian Flash Communicator make secure data exchange among authenticated applications and people straightforward and affordable for any organization, regardless of size and resources. Validian products also facilitate security audit compliance and assurance, whether mandated by government, industry or internal policy, prevent application and end user impersonation, and deliver confidentiality through true end-to-end encryption of all exchanges, so that data never travels in the clear. A U.S. corporation, Validian has offices in the United States, Canada and Switzerland.

"Safe Harbor" Statements under the Private Securities Litigation Reform Act of 1995: Investors should carefully consider the preceding information as well as information contained in this news release before making an investment in the shares of the company. Information contained in this news release, which are not historical facts, including those that refer to Validian’s plans, beliefs and intentions, are "forward looking statements", which can be identified by the use of forward-looking terminology such as "believes," expects," "may," "should," or "anticipates" or negative thereof or given that the future results covered by such forward -looking statements will be achieved. The preceding matters constitute cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause actual results to vary materially from the future statements as a result of certain factors set forth under Risk Factors and elsewhere in the Company’s Annual Report on Form 10-KSB with the Securities and Exchange Commission on April 14, 2005.